|Bid||32.47 x 800|
|Ask||32.48 x 1800|
|Day's Range||31.81 - 32.57|
|52 Week Range||28.00 - 37.61|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||117.36|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.27|
Is Elanco Animal Health Incorporated (NYSE:ELAN) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus […]
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have set Eli Lilly and Company’s (LLY) 12-month consensus target price at $122, 2.59% lower than
INDIANAPOLIS, March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) previously owned by Lilly, which expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Because the exchange offer was oversubscribed, Lilly accepted only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Lilly common stock, or an "odd-lot," who validly tendered all of their shares, were not subject to proration, in accordance with the terms of the exchange offer.
Elanco Animal Health Incorporated (ELAN) today announced the appointment of four new members to the Board of Directors. The Board was initially established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company. The appointments follow Lilly’s full divestiture of Elanco, making Elanco a fully independent company.
Why Eli Lilly Stock Fell YesterdayStock price movements Yesterday, Eli Lilly (LLY) closed at $123.50, 2.53% lower than its previous closing price, 65.75% higher than its 52-week low of $74.51, and 5.37% below its 52-week high of $130.51. The
Elanco completed its initial public offering in September 2018, at which point Eli Lilly was a majority shareholder with an 80.2-percent stake. Shareholders could exchange all, some or none of their Eli Lilly stock. The ultimate exchange ratio was settled at 4.5121 shares of Elanco common stock for each share of Eli Lilly common stock.
Elanco Animal Health Incorporated (ELAN) today announced that it is now a fully independent company. The completion of Eli Lilly and Company’s exchange offer completes the journey Elanco began in 2017 when its former parent company first announced the exploration of potential strategic alternatives for the 64-year-old animal health company. The exchange offer was 7.6x oversubscribed.
INDIANAPOLIS, March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) owned by Lilly was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Under the terms of the exchange offer, 4.5121 shares of Elanco common stock will be exchanged for each share of Lilly common stock accepted in the exchange offer.
INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (ELAN) owned by Lilly. For each share of Lilly common stock that is validly tendered and not validly withdrawn by shareholders and that is accepted pursuant to the exchange offer, Lilly will deliver 4.5121 shares of Elanco common stock to or at the direction of any such tendering shareholder.
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) confirmed its fiscal 2019 guidance
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?Stock price movementsOn February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and
Warning! GuruFocus has detected 2 Warning Sign with ELAN. For the last quarter Elanco Animal Health Inc reported a revenue of $799.3 million, compared with the revenue of $697.1 million during the same period a year ago. The Elanco Animal Health Inc had a decent operating margin of 10.23%, compared with the operating margin of 4.93% a year before.
Investors need to pay close attention to Elanco Health (ELAN) stock based on the movements in the options market lately.
The drug giant announced on Friday that it will unload the remaining shares it holds of Elanco Animal Health through a voluntary stock-exchange offer.
Elanco Animal Health Incorporated (ELAN), formerly the animal health business of Eli Lilly and Company (Lilly), today announced it intends to file a Form S-4 Registration Statement with the Securities and Exchange Commission (SEC) in connection with Lilly’s proposed exchange offer whereby Lilly shareholders can exchange shares of Lilly common stock for shares of Elanco common stock owned by Lilly. The exchange offer is anticipated to be tax-free for participating Lilly shareholders in the United States, except with respect to cash received in lieu of fractional shares.
Eli Lilly and Co. said Friday it will divest its remaining stake in Elanco Animal Health via an exchange offer. Lilly shareholders will be able to exchange all, some of none of their shares of Lilly common stock for Elanco common stock owned by Lilly. The company retained an 80.2% stake, or 293.29 million shares, in the animal health company when it completed its IPO in September of 2018. "It's the right time to finalize the separation, let Elanco chart its future as a standalone company, and focus Lilly on our core mission to create human medicines that make life better for people around the world," Lilly Chief Executive David Ricks said in a statement. Lilly shareholders will be able to exchange their shares for Elanco shares at a 7% discount, subject to an upper limit of 4.5262 shares of Elanco stock per Lilly share. If the upper limit is not in effect, for each $100 of shares of Lilly common stock accepted in the exchange offer, tendering shareholders would receive approximately $107.53 of Elanco common stock. "These values will be determined by reference to the simple arithmetic average of the daily volume-weighted average prices of Lilly common stock and Elanco common stock on the New York Stock Exchange during the three consecutive trading days ending on and including the second trading day preceding the expiration date of the exchange offer, which would be March 4, March 5, and March 6, 2019, if the exchange offer is not extended or terminated," said the statement. Lilly shares rose 1.8% in premarket trade and have gained 58.3% in the last 12 months, while the S&P 500 has gained 4.9%.
INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (ELAN). Elanco completed its initial public offering (IPO) in September 2018, with Lilly retaining an 80.2 percent ownership interest in Elanco. In the exchange offer, Lilly shareholders can exchange all, some or none of their shares of Lilly common stock for shares of Elanco common stock owned by Lilly, subject to possible proration as described below.
Full year global revenue increased 6 percent to $3.1 billion, Interceptor® Plus reaches blockbuster status with more than $100 million in annual sales
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Elanco Animal Health (ELAN) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. Elanco will also conduct a conference call with the investment community and media on that day to further detail the company's financial performance. Elanco (ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.
Performance Livestock Analytics, Inc. and Elanco Animal Health Incorporated , today announce an agreement to provide joint customers data from PLA’s fast-growing Performance Beef TM platform and access to Elanco’s Benchmark ® service.